Article Text
Editorial
Results of the early stage PD MED study: revelation or recapitulation?
Statistics from Altmetric.com
Footnotes
Correction notice This paper has been amended since it was published Online First. The second paragraph has been rewritten. Also on the first page, top of the second column the author cites a study published by The Lancet about the results of the long-awaited early stage PD MED study. The reference to this study has been added to the reference list.
Competing interests PW has received honoraria and consulting fees from Medtronic, Boehringer-Ingelheim, UCB Pharma, Brittania, Abbvie, Teva and Lundbeck.
Provenance and peer review Commissioned; externally peer reviewed. This paper was reviewed by Simon Lewis, Sydney, Australia.
Read the full text or download the PDF:
Other content recommended for you
- When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
- Parkinson’s disease: etiopathogenesis and treatment
- Pharmacological treatment of Parkinson's disease
- Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease
- ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease
- Initial drug treatment in Parkinson’s disease
- Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
- Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
- Dopamine agonists: their role in the treatment of Parkinson's disease
- Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels